Sulbutiamine vs PE-22-28
Side-by-side comparison of Sulbutiamine and PE-22-28: mechanism, half-life, dose range, safety profile, and vendor pricing.
Price snapshot
Sulbutiamine
PE-22-28
Sulbutiamine
Sulbutiamine (chemical name: isobutyryl thiamine disulfide; trade names include Arcalion, Enerion, Bisibutiamine) is a lipophilic synthetic derivative of vitamin B1 (thiamine), developed in Japan in the 1960s by Sankyo…
No vendor price on file.
Full Sulbutiamine profilePE-22-28
PE-22-28 is a synthetic seven-amino-acid peptide (sequence PAGASRLLLLTGEIDLP derivative, commonly truncated to PE-22-28 as shorthand for "position 22-28" within the parent humanin-family sequence) that was designed as an…
Lowest listed price: $49.99 across 1 listing
Full PE-22-28 profileSide-by-side comparison
| Attribute | Sulbutiamine | PE-22-28 |
|---|---|---|
| Category | Nootropics | Nootropics |
| Research Stage | Preclinical | Preclinical |
| Mechanism of Action | Sulbutiamine's mechanism of action is thought to combine enhanced thiamine delivery to the central nervous system with additional neurotransmitter-level effects that the water-soluble parent vitamin does not readily produce. The mechanism has been… | PE-22-28 is a synthetic 7-amino-acid peptide (sequence GVSWGLR) and a shortened analog of spadin. Its proposed mechanism is inhibition of the TREK-1 (TWIK-related K+) channel, a two-pore-domain potassium channel (K2P2.1 / KCNK2) implicated in mood regulation.… |
| Half-Life | — | Not characterized in humans. As a small 7-amino-acid peptide a short plasma half-life is expected; in mice the parent peptide spadin lost antidepressant activity by about 7 hours after a single dose, while modified analogs (e.g., G/A-PE 22-28) extended the behavioral effect to roughly 21-23 hours [PMID:28955242]. |
| Typical Dose Range | — | 250-2000 mcg subcutaneous per dose (empirical research-chemical community range; no clinically validated human dose exists; effective preclinical rodent doses were far lower, ~3 mcg/kg). |
| Dosing Frequency | — | Once daily or every other day (research-chemical community protocols; no validated clinical dosing schedule). |
| Administration | — | — |
| Side Effects | Sulbutiamine has a generally favourable safety profile in French clinical practice and in PubMed-indexed studies, but — as with any compound used off-label or outside rigorous regulatory oversight — users should understand both the common tolerability profile… | No human side-effect data exist for PE-22-28 because it has never been tested in people. What can be said comes from rodent studies of PE-22-28, spadin and their analogs, plus general considerations for injected research peptides. In the preclinical work, the… |
| Molecular Weight | 702.89 g/mol | 773.9 g/mol |
| Common Vial Sizes | — | — |
Price History
2 data pointsSulbutiamine: potential benefits
- Motivation enhancement
- Memory improvement
- Fatigue reduction
- Mood elevation
- Dopamine D1 upregulation
- Erectile function
PE-22-28: potential benefits
- Antidepressant-like effects in rodent models of depression (preclinical only)
- Potent, selective inhibition of the TREK-1 (K2P2.1) potassium channel (IC50 ~0.12 nM)
- Rapid-onset (~4-day) antidepressant profile in animals, unlike the multi-week lag of SSRIs
- Increased hippocampal neurogenesis in mice
- Increased cortical synaptogenesis (PSD-95) and BDNF expression in preclinical studies
- No human-validated benefits; not approved for any use (research use only)
Frequently asked
What's the difference between Sulbutiamine and PE-22-28?
Sulbutiamine is a nootropics that sulbutiamine's mechanism of action is thought to combine enhanced thiamine delivery to the central nervous system with additional neurotransmitter-level effects that the…. PE-22-28 is a nootropics that pe-22-28 is a synthetic 7-amino-acid peptide (sequence gvswglr) and a shortened analog of spadin. its proposed mechanism is inhibition of the trek-1 (twik-related k+) channel, a…. The two differ in mechanism, half-life (not reported vs Not characterized in humans. As a small 7-amino-acid peptide a short plasma half-life is expected; in mice the parent peptide spadin lost antidepressant activity by about 7 hours after a single dose, while modified analogs (e.g., G/A-PE 22-28) extended the behavioral effect to roughly 21-23 hours [PMID:28955242].), and typical dose range.
Which has the longer half-life, Sulbutiamine or PE-22-28?
Sulbutiamine has a half-life of not reported. PE-22-28 has a half-life of Not characterized in humans. As a small 7-amino-acid peptide a short plasma half-life is expected; in mice the parent peptide spadin lost antidepressant activity by about 7 hours after a single dose, while modified analogs (e.g., G/A-PE 22-28) extended the behavioral effect to roughly 21-23 hours [PMID:28955242].. Longer half-lives generally mean less frequent dosing but slower on/off kinetics.
Can you stack Sulbutiamine and PE-22-28?
Stacking depends on mechanism overlap, safety profile, and goals. Sulbutiamine and PE-22-28 should only be stacked after reviewing each compound's individual protocol page, side effect profile, and any published interaction data. Use the BodyHackGuide stack builder for a structured review before combining research compounds.
See current vendor prices
Listings from the vendors we track. Prices change often, so check the vendor before you buy.
Before you buy Sulbutiamine or PE-22-28
Check the vendor trust score. Every supplier we track is rated 0-100 on COA verification, payment transparency, shipping, reviews, and listings: one published, reproducible methodology, applied to every vendor.
Related comparisons
Research use only. BodyHackGuide is a research and price-comparison reference. The compounds discussed on this page are not approved by the FDA for human consumption and are sold strictly for laboratory research. Prices shown are pulled from vendor listings tracked on BHG and are subject to change. Every vendor is ranked on the same public, reproducible methodology. See editorial standards and affiliate disclosure.